Search Results - "Pearson, Steven D."

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs by Bach, Peter B, Pearson, Steven D

“…Prescription drugs is the only major category of health care services for which the producer is able to exercise relatively unrestrained pricing power. By law,…”
Get full text

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions by Sculpher, Mark, MSc, PhD, Claxton, Karl, MSc, PhD, Pearson, Steven D., MSc, MD

“…Abstract A growing number of health care systems internationally use formal economic evaluation methods to support health care funding decisions. Recently, a…”
Get full text

Cost, Coverage, and Comparative Effectiveness Research: The Critical Issues for Oncology by Pearson, Steven D

“…A new national initiative in comparative effectiveness research (CER) is part of a broad and long-term evolution toward greater reliance on scientific evidence…”
Get full text

Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure by Stutz, Matthew R., Dylla, Nicholas P., Pearson, Steven D., Lecompte-Osorio, Paola, Nayak, Ravi, Khalid, Maryam, Adler, Emerald, Boissiere, Jaye, Lin, Huaiying, Leiter, William, Little, Jessica, Rose, Amber, Moran, David, Mullowney, Michael W., Wolfe, Krysta S., Lehmann, Christopher, Odenwald, Matthew, De La Cruz, Mark, Giurcanu, Mihai, Pohlman, Anne S., Hall, Jesse B., Chaubard, Jean-Luc, Sundararajan, Anitha, Sidebottom, Ashley, Kress, John P., Pamer, Eric G., Patel, Bhakti K.

“…Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated…”
Get full text

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis by Whittington, Melanie D., MS, McQueen, R. Brett, PhD, Ollendorf, Daniel A., PhD, Tice, Jeffrey A., MD, Chapman, Richard H., PhD, MS, Pearson, Steven D., MD, MSc, Campbell, Jonathan D., PhD

“…Abstract Background Adding mepolizumab to standard treatment with inhaled corticosteroids and controller medications could decrease asthma exacerbations and…”
Get full text

White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market by Pearson, Caroline, Schapiro, Lindsey, Pearson, Steven D

“…New Institute for Clinical and Economic Review (ICER) analysis evaluates potential risks and advantages of reforms to current policies related to white…”
Get full text

Bedside estimates of dead space using end-tidal CO2 are independently associated with mortality in ARDS by Lecompte-Osorio, Paola, Pearson, Steven D, Pieroni, Cole H, Stutz, Matthew R, Pohlman, Anne S, Lin, Julie, Hall, Jesse B, Htwe, Yu M, Belvitch, Patrick G, Dudek, Steven M, Wolfe, Krysta, Patel, Bhakti K, Kress, John P

“…Abstract Purpose In acute respiratory distress syndrome (ARDS), dead space fraction has been independently associated with mortality. We hypothesized that…”
Get full text

Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies by Pearson, Steven D, Singh, Prabhjot, Beaudoin, Francesca, Campbell, Jon, Schapiro, Lindsey, Emond, Sarah K, Pearson, Caroline

“…Digital health technologies (DHTs) are a broad and rapidly innovating class of interventions with distinctive pathways for development, regulatory approval,…”
Get full text

Indication-specific pricing of pharmaceuticals in the US healthcare system by Pearson, Steven D, Dreitlein, William B, Henshall, Chris, Towse, Adrian

“…To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system. The…”
Get full text

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value by Pearson, Steven D.

“…What should be the relationship between the concepts of cost effectiveness and affordability in value assessments for health care interventions? This question…”
Get full text

Patients' Trust in Physicians: Many Theories, Few Measures, and Little Data by Pearson, Steven D., Raeke, Lisa H.

“…Trust is one of the central features of patient‐physician relationships. Rapid changes in the health care system are feared by many to be threatening patients'…”
Get full text

Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer by MULLINS, C. Daniel, MONTGOMERY, Russ, ABERNETHY, Amy P, HUSSAIN, Arif, PEARSON, Steven D, TUNIS, Sean

“…To provide recommendations to trialists and sponsors that guide the design and implementation of prospective postapproval clinical trials for oncology drugs…”
Get full text

The Patient Not in the Room by Pearson, Steven D

“…In their article, Vanness and colleagues explore the best way to establish a cost-effectiveness threshold for policy considerations. This may seem an arcane…”
Get full text

Public participation in decision-making on the coverage of new antivirals for hepatitis C by Kieslich, Katharina, Ahn, Jeonghoon, Badano, Gabriele, Chalkidou, Kalipso, Cubillos, Leonardo, Hauegen, Renata Curi, Henshall, Chris, Krubiner, Carleigh B, Littlejohns, Peter, Lu, Lanting, Pearson, Steven D, Rid, Annette, Whitty, Jennifer A, Wilson, James

“…Purpose – New hepatitis C medicines such as sofosbuvir underline the need to balance considerations of innovation, clinical evidence, budget impact and equity…”
Get full text

Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the “Optimal” Oral Anticoagulant for Atrial Fibrillation by Cameron, Christopher G., PhD, Synnott, Patricia G., MS, MALD, Pearson, Steven D., MD, MSc, Dubois, Robert W., MD, PhD, Ciarametaro, Michael, MBA, Ollendorf, Daniel A., PhD

“…Abstract Objectives To investigate heterogeneity of treatment effect (HTE) for anticoagulants in atrial fibrillation across subgroups defined by 1) clinical…”
Get full text

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease by Whittington, Melanie D., Campbell, Jonathan D., Rind, David, Fluetsch, Noemi, Lin, Grace A., Pearson, Steven D.

“…Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject…”
Get full text

Why the Coming Debate Over the QALY and Disability Will be Different by Pearson, Steven D.

“…The QALY has served for over 30 years as the gold standard within health economics for measuring the impact of treatments on patients' health. Created with the…”
Get full text

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease by Kazi, Dhruv S, Moran, Andrew E, Coxson, Pamela G, Penko, Joanne, Ollendorf, Daniel A, Pearson, Steven D, Tice, Jeffrey A, Guzman, David, Bibbins-Domingo, Kirsten

“…IMPORTANCE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently approved for lowering low-density lipoprotein cholesterol in…”
Get full text

Evolving targets for sedation during mechanical ventilation by Pearson, Steven D., Patel, Bhakti K.

“…Critically ill patients frequently require mechanical ventilation as part of their care. Administration of analgesia and sedation to ensure patient comfort and…”
Get full text

Value assessment and heterogeneity: another side to the story by Pearson, Steven D

“…The founder and president of the Institute for Clinical and Economic Review responds to the commentary on heterogeneity in value assessment…”
Get full text